-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $85

Benzinga·06/16/2026 13:28:14
Listen to the news
Morgan Stanley analyst Sean Laaman maintains Disc Medicine (NASDAQ:IRON) with a Overweight and raises the price target from $80 to $85.